TrialCancer chemotherapy and pharmacology2021

Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin.

Helena Taflin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.